Bictegravir+emtricitabine+tenofovir alafenamide and dolutegravir+rilpivirine for HIV Skip to navigationSkip to contentA-Z MedicinesFAQSubscribeSearchSearchSearch medicinePBS MEDICINE SEARCHHomePBS InformationBrowse the PBSFor Health ProfessionalsFor IndustryNewsPublications & DownloadsContactsHome/ Industry/ Listing/ Participants/ Public Release Docs/ 2021 10/ Bictegravir Emtricitabine Tenofovir Alafenamide And DolutegrBictegravir+emtricitabine+tenofovir alafenamide and dolutegravir+rilpivirine for HIV, October 2021Page last updated: 24 March 2022Drug utilisation sub-committee (DUSC)October 2021AbstractPurposeTo review the predicted versus actual utilisation of bictegravir+emtricitabine+tenofovir alafenamide (Biktarvy) and dolutegravir+rilpivirine (Juluca) in the first 24 months of R/PBS
Dolutegravir + rilpivirine (Juluca) dual therapy in HIV infection Prescrire IN ENGLISH - Spotlight ''Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection'', 1 November 2019 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues Topics * Annual Prescrire Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90Spotlight * 100 most recent
The steady-state pharmacokinetics of fixed-dose combination dolutegravir+rilpivirine in hemodialysis. Fixed dose combination (FDC) dolutegravir (DTG) plus rilpivirine (RPV) is an approved antiretroviral treatment regimen for people with HIV. The steady-state pharmacokinetics of FDC DTG+RPV in hemodialysis has not been previously studied. We performed a single-center, prospective evaluation
Dolutegravir/rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Dolutegravir/Rilpivirin (HIV-Infektion) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 September 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-34 Dolutegravir/rilpivirine (HIV infection) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A18-34 Version 1.0 Dolutegravir/rilpivirine (HIV infection
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies. SWORD-1 and SWORD-2 phase 3 studies concluded that switching virologically suppressed participants with HIV-1 from their current three- or four-drug antiretroviral regimen (CAR) to the two-drug regimen of once-daily dolutegravir (DTG, 50 mg
Dolutegravirrilpivirine (Juluca) - For the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA copies <50 copies/mL) on a stable antiretroviral regimen Published 10 September 2018 1 dolutegravir 50mg / rilpivirine 25mg film-coated tablets (Juluca®) SMC2091 ViiV Healthcare Ltd. 10 August 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission dolutegravir / rilpivirine film-coated tablet (Juluca®) is accepted for use within NHSScotland. Indication under review: The treatment of human
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials. The SWORD trials showed that in participants who achieved virologic suppression taking 3-drug or 4-drug regimens, switching to the 2-drug regimen dolutegravir plus rilpivirine
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lifelong HIV antiretroviral therapy (ART) has prompted an interest in two-drug regimens to minimise cumulative drug exposure and toxicities. The safety, tolerability, and efficacy of dolutegravir 25, 2015, for SWORD-2. We randomly assigned 516 participants to dolutegravir-rilpivirine and 512 to continue with CAR. At week 48 (last patient visit was Nov 22, 2016), in the pooled analysis of the intention-to-treat population, 95% of participants had viral loads lower than 50 copies per mL in each group (486 of 513 in the dolutegravir-rilpivirine group vs 485 of 511 in the CAR group
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Primary analyses of the SWORD-1 and SWORD-2 trials at 48 weeks showed that switching to a two-drug regimen of dolutegravir plus rilpivirine was non-inferior to continuing a standard three-drug or four
Dolutegravir-rilpivirine coformulation. With prolonged life expectancy in HIV-positive patients on combination antiretroviral therapy, the quest for reducing lifelong drug exposure and minimizing or avoiding the toxicities of combination antiretroviral therapy while maintaining viral suppression has emerged when coformulations of antiretroviral agents with improved convenience, and better
Dolutegravir/rilpivirine for the treatment of HIV-1 infection Much progress has been made in the development of antiretroviral therapies (ARTs) for HIV-1 infection. Beginning a little over a decade ago, single tablet combination regimens (STRs) became available, and subsequently, newer STR formulations with improved safety profiles have emerged. Recently, there is a growing interest in regimen simplification with the primary goal of further reducing long-term toxicities of ART and improving medication adherence. Dolutegravir/rilpivirine (DTG/RPV) was approved by the US Food and Drug Administration (FDA) as the first dual antiretroviral STR for the maintenance therapy of HIV-1 infection. Following an extensive review of all published papers on RPV and DTG, administered alone and in combination
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA [Ribonucleic Acid] < 50 [cells per milliliter] c/mL) children 6 to less than 12 years
/2018Last updated: 24/05/2018ViewSuomi (FI) (6.97 KB - PDF) First published: 24/05/2018Last updated: 24/05/2018Viewsvenska (SV) (11.65 KB - PDF) First published: 24/05/2018Last updated: 24/05/2018ViewProduct detailsName of medicine Juluca Active substance * dolutegravir sodium * rilpivirine hydrochloride International non-proprietary name (INN) or common name * dolutegravir * rilpivirine Therapeutic area
boosted atazanavir; ritonavir boosted darunavir; dolutegravir; cobicistat boosted elvitegravir; raltegravir or rilpivirine.3, 8 There are a number of single tablet combination products available which aim to improve adherence to combination regimens and dual therapy regimens are also available, for example dolutegravir / rilpivirine (Juluca®) and dolutegravir / lamivudine (Dovato®). Cabotegravir ), emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey®), dolutegravir/lamivudine (Dovato®), dolutegravir/rilpivirine (Juluca®) and two multi-tablet regimens: emtricitabine/tenofovir alafenamide plus dolutegravir (Descovy® plus Tivicay®) and emtricitabine/tenofovir alafenamide plus raltegravir (Descovy® plus Isentress®). The analysis adopted a life-time horizon of 80 years. The economic analysis